Age-related macular degeneration: experimental and emerging treatments

Jean Pierre Hubschman, Shantan Reddy, Steven D SchwartzJules Stein Eye Institute, Department of Ophthalmology, University of California, David Geffen School of Medicine, Los Angeles, California, USAPurpose: This essay reviews the experimental treatments and new imaging modalities that are currently...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jean Pierre Hubschman, Shantan Reddy, Steven D Schwartz
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2009
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/d8b1ef61587c4d6085e1d6fdd229b06f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d8b1ef61587c4d6085e1d6fdd229b06f
record_format	dspace
spelling	oai:doaj.org-article:d8b1ef61587c4d6085e1d6fdd229b06f2021-12-02T06:37:39ZAge-related macular degeneration: experimental and emerging treatments1177-54671177-5483https://doaj.org/article/d8b1ef61587c4d6085e1d6fdd229b06f2009-01-01T00:00:00Zhttp://www.dovepress.com/age-related-macular-degeneration-experimental-and-emerging-treatments-a2790https://doaj.org/toc/1177-5467https://doaj.org/toc/1177-5483Jean Pierre Hubschman, Shantan Reddy, Steven D SchwartzJules Stein Eye Institute, Department of Ophthalmology, University of California, David Geffen School of Medicine, Los Angeles, California, USAPurpose: This essay reviews the experimental treatments and new imaging modalities that are currently being explored by investigators to help treat patients with age-related macular degeneration (AMD).Design: Interpretative essay.Methods: Literature review and interpretation.Results: Experimental treatments to preserve vision in patients with exudative AMD include blocking vascular endothelial growth factor (VEGF), binding VEGF, and modulating the VEGF receptors. Investigators are also attempting to block signal transduction with receptor tyrosine kinase inhibitors. Experimental treatments for non-exudative AMD include agents that target inflammation, oxidative stress, and implement immune-modulation. The effectiveness of these newer pharmacologic agents has the potential to grow exponentially when used in combination with new and improved imaging modalities that can help identify disease earlier and follow treatment response more precisely.Conclusion: With a better understanding, at the genetic and molecular level, of AMD and the development of superior imaging modalities, investigators are able to offer treatment options that may offer unprecedented visual gains while reducing the need for repetitive treatments.Keywords: age-related macular degeneration, VEGF, SiRNA, PEDF Jean Pierre HubschmanShantan ReddySteven D SchwartzDove Medical PressarticleOphthalmologyRE1-994ENClinical Ophthalmology, Vol 2009, Iss default, Pp 167-174 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ophthalmology RE1-994
spellingShingle	Ophthalmology RE1-994 Jean Pierre Hubschman Shantan Reddy Steven D Schwartz Age-related macular degeneration: experimental and emerging treatments
description	Jean Pierre Hubschman, Shantan Reddy, Steven D SchwartzJules Stein Eye Institute, Department of Ophthalmology, University of California, David Geffen School of Medicine, Los Angeles, California, USAPurpose: This essay reviews the experimental treatments and new imaging modalities that are currently being explored by investigators to help treat patients with age-related macular degeneration (AMD).Design: Interpretative essay.Methods: Literature review and interpretation.Results: Experimental treatments to preserve vision in patients with exudative AMD include blocking vascular endothelial growth factor (VEGF), binding VEGF, and modulating the VEGF receptors. Investigators are also attempting to block signal transduction with receptor tyrosine kinase inhibitors. Experimental treatments for non-exudative AMD include agents that target inflammation, oxidative stress, and implement immune-modulation. The effectiveness of these newer pharmacologic agents has the potential to grow exponentially when used in combination with new and improved imaging modalities that can help identify disease earlier and follow treatment response more precisely.Conclusion: With a better understanding, at the genetic and molecular level, of AMD and the development of superior imaging modalities, investigators are able to offer treatment options that may offer unprecedented visual gains while reducing the need for repetitive treatments.Keywords: age-related macular degeneration, VEGF, SiRNA, PEDF
format	article
author	Jean Pierre Hubschman Shantan Reddy Steven D Schwartz
author_facet	Jean Pierre Hubschman Shantan Reddy Steven D Schwartz
author_sort	Jean Pierre Hubschman
title	Age-related macular degeneration: experimental and emerging treatments
title_short	Age-related macular degeneration: experimental and emerging treatments
title_full	Age-related macular degeneration: experimental and emerging treatments
title_fullStr	Age-related macular degeneration: experimental and emerging treatments
title_full_unstemmed	Age-related macular degeneration: experimental and emerging treatments
title_sort	age-related macular degeneration: experimental and emerging treatments
publisher	Dove Medical Press
publishDate	2009
url	https://doaj.org/article/d8b1ef61587c4d6085e1d6fdd229b06f
work_keys_str_mv	AT jeanpierrehubschman agerelatedmaculardegenerationexperimentalandemergingtreatments AT shantanreddy agerelatedmaculardegenerationexperimentalandemergingtreatments AT stevendschwartz agerelatedmaculardegenerationexperimentalandemergingtreatments
_version_	1718399840878067712

Age-related macular degeneration: experimental and emerging treatments

Ejemplares similares